[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Liu Qiang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,60],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100638823","phase-3-clinical-study-of-chinese-herbal-compound-qidan-xiaoke-granules-in-patients-after-coronary-revascularization-100638823",false,"NCT07616544","Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization","Inclusion Criteria:\n\n1. Age: 18-80 years old;\n2. no gender limitation;\n3. Meets the diagnostic criteria for coronary heart disease;\n4. Accepts effective PCI procedure;\n5. Voluntarily participates and signs a written informed consent form.\n\nExclusion Criteria:\n\n1. Severe hepatic and\u002For renal insufficiency\n2. Severe electrolyte disorders\n3. Severe hematological diseases or malignant tumors\n4. Pregnant or breastfeeding women\n5. Patients with mental illness\n6. Cognitive impairment (e.g., dementia, post-stroke cognitive impairment) leading to inability to communicate normally\n7. Planning to undergo another revascularization surgery in the near future\n8. Other severe cardiovascular diseases (e.g., uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block without a pacemaker implanted, acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, acute aortic dissection, etc.)\n9. Acute pulmonary embolism and chronic lung diseases with dyspnea symptoms (occurring at rest or with minimal exertion)\n10. Explicit exclusion criteria (bleeding history within 1 month, active bleeding, bleeding tendency, currently using anticoagulants)\n11. Participants in other interventional clinical trials within the past month\n12. Allergy to known components of the investigational drug (Qidan Xiaohe Granules)\n13. Other conditions deemed unsuitable for participation in the trial by the investigator","ALL","18 Years","80 Years",{"count":19,"type":20},164,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","1. Evaluate the efficacy and safety of Qidan Xiaohe granules in patients after coronary revascularization surgery;\n2. Develop a traditional Chinese medicine rehabilitation treatment plan and evaluation system for the use of Qidan Xiaohe granules after coronary revascularization surgery;\n3. Demonstrate the advantages of traditional Chinese medicine rehabilitation treatment in the postoperative management of coronary revascularization surgery and provide high-level evidence-based medical evidence for the development of traditional Chinese medicine rehabilitation treatment plans.",[26,27,28],"Percutaneous Coronary Intervention","Myocardial Revascularization","Coronary Artery Disease","NOT_YET_RECRUITING","2026-05-27",{"date":32,"type":33},"2026-06-01","ACTUAL",{"date":35,"type":20},"2026-07-01",{"date":37,"type":20},"2028-12-31",{"name":39,"class":40},"Liu Qiang","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":59,"locationsCount":4},"100639444","establishment-of-disease-characteristics-and-a-chinese-medicine-prognosis-risk-model-based-on-a-large-scale-database-after-coronary-revascularization-100639444","NCT07613060","Establishment of Disease Characteristics and a Chinese Medicine Prognosis Risk Model Based on a Large-Scale Database After Coronary Revascularization","Inclusion Criteria:\n\n* Diagnosis of coronary artery disease with prior coronary revascularization (PCI or CABG)\n* Age ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Malignant arrhythmias, severe heart failure, myocardial disease, or structural heart disease\n* Severe pulmonary insufficiency, severe liver or kidney dysfunction, severe electrolyte disturbances\n* Pregnancy or breastfeeding\n* Severe psychiatric disorders, malignant tumors, hematologic diseases, rheumatic immune diseases, or severe infection\n* Poor compliance or any other reason making the participant unsuitable for the study",{"count":48,"type":20},600,"12 Months","OBSERVATIONAL","This study aims to develop a risk prediction model for patients who have undergone coronary revascularization (such as stent placement or bypass surgery). After these procedures, some patients still experience heart-related problems like chest pain, heart attack, or rehospitalization. This study will enroll 600 patients from multiple hospitals in China and follow them for 12 months. At enrollment and at 12, 24, 36, and 48 weeks after surgery, researchers will collect clinical information (including traditional Chinese medicine symptoms, blood tests, heart imaging) and biological samples (blood and tongue coating). Using artificial intelligence, the study will build a predictive model that combines Western medical data with traditional Chinese medicine characteristics. The goal is to better identify patients at higher risk of future heart events, so that personalized prevention and management can be provided. The study does not involve any experimental treatment or intervention - it is purely observational.",[28,53,27],"Postoperative Period","2026-05-21",{"date":56,"type":33},"2026-05-29",{"date":35,"type":20},{"date":37,"type":20},{"name":39,"class":40},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":76,"locationsCount":4},"100639118","baduanjin-intervention-in-clinical-studies-after-coronary-revascularization-surgery-100639118","NCT07607951","Baduanjin Intervention in Clinical Studies After Coronary Revascularization Surgery","Inclusion Criteria:\n\n* Participants who meet the diagnostic criteria for coronary heart disease\n* Participants who underwent successful percutaneous coronary intervention\n* Participants aged between 18 and 80\n* Participants of any gender\n* Participants who have signed an informed consent form\n\nExclusion Criteria:\n\n* Subjects with severe hepatic or renal impairment\n* subjects with severe electrolyte disturbances\n* subjects with severe haematological disorders or malignant tumours\n* pregnant or breastfeeding women\n* subjects with psychiatric disorders\n* subjects with cognitive impairment (e.g. dementia, post-stroke cognitive impairment) that prevents them from understanding or carrying out exercise instructions\n* Subjects scheduled to undergo repeat revascularisation surgery in the near future\n* Subjects with other severe cardiovascular diseases such as uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block (without a pacemaker), acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, or acute aortic dissection\n* Participants with acute pulmonary embolism or chronic lung disease accompanied by symptoms of dyspnoea (occurring at rest or with minimal exertion)\n* Subjects with impaired limb mobility or who are unable to move independently;\n* Subjects with Shy-Drager syndrome\n* Subjects who have participated in a clinical trial involving other drugs or exercise interventions within the past month\n* Subjects deemed by the investigator to have other conditions rendering them unsuitable for participation in the trial",{"count":67,"type":20},310,[69],"NA","1. To evaluate the efficacy and safety of the Baduanjin exercise programme in patients following coronary revascularisation surgery;\n2. To develop a traditional Chinese medicine (TCM) rehabilitation protocol and evaluation system for patients following coronary revascularisation surgery;\n3. To clarify the advantages of TCM rehabilitation in the post-operative management of coronary revascularisation surgery and to provide high-level evidence-based medical evidence for TCM rehabilitation protocols.",[26,27,28],"2026-05-19",{"date":30,"type":33},{"date":35,"type":20},{"date":37,"type":20},{"name":39,"class":40},""]